27 Mar 2020 --- Therapy with icosapent ethyl, a purified stable eicosapentaenoic acid (EPA), could help prevent more than 70,000 cardiovascular events per year in US adults with a history of cardiovascular disease (CVD) or diabetes mellitus. This is the conclusion of a multinational clinical trial called REDUCE-IT conducted at the University of California, Irvine (UCI), US, that will be presented at the upcoming ACC.20/World Congress of Cardiology conference. As heart health remains a constant national concern, this study provides a promising avenue for further research on long-term preventive measures to cardiovascular events via supplementation.
